Simcere Pharmaceutical Group Limited (HKG:2096)

Market Cap	34.50B
Revenue (ttm)	7.79B
Net Income (ttm)	964.48M
Shares Out	2.47B
EPS (ttm)	0.39
PE Ratio	35.54
Forward PE	25.54
Dividend	0.17 (1.24%)
Ex-Dividend Date	Jun 18, 2025

Volume	9,101,000
Average Volume	30,334,068
Open	14.18
Previous Close	14.13
Day's Range	13.83 - 14.30
52-Week Range	5.86 - 15.08
Beta	0.52
RSI	56.19
Earnings Date	Aug 21, 2025

About HKG:2096

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENW...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 6,584
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2096

Financial Performance

In 2024, HKG:2096's revenue was 6.64 billion, an increase of 0.41% compared to the previous year's 6.61 billion. Earnings were 733.17 million, an increase of 2.57%.

Financial numbers in CNY